Related references
Note: Only part of the references are listed.MEK'ing the Most of p53 Reactivation Therapy in Melanoma
John T. Lee et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
The molecular pathology of cutaneous melanoma
Thomas Bogenrieder et al.
CANCER BIOMARKERS (2011)
6-Bromoindirubin-3′-Oxime Inhibits JAK/STAT3 Signaling and Induces Apoptosis of Human Melanoma Cells
Lucy Liu et al.
CANCER RESEARCH (2011)
Resistance to BRAF Inhibitors: Unraveling Mechanisms and Future Treatment Options
Jessie Villanueva et al.
CANCER RESEARCH (2011)
Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
Mohammad Atefi et al.
PLOS ONE (2011)
Identification of MET and SRC Activation in Melanoma Cell Lines Showing Primary Resistance to PLX4032
Elisabetta Vergani et al.
NEOPLASIA (2011)
Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail
Gajanan S. Inamdar et al.
BIOCHEMICAL PHARMACOLOGY (2010)
The PKB/AKT Pathway in Cancer
Amancio Carnero
CURRENT PHARMACEUTICAL DESIGN (2010)
5,5′-Substituted Indirubin-3′-oxime Derivatives as Potent Cyclin-Dependent Kinase Inhibitors with Anticancer Activity
Soo-Jeong Choi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Phosphoinositide signalling in cancer: beyond PI3K and PTEN
Tom D. Bunney et al.
NATURE REVIEWS CANCER (2010)
Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Janus kinases in immune cell signaling
Kamran Ghoreschi et al.
IMMUNOLOGICAL REVIEWS (2009)
CANCER RESEARCH Melanoma Drug Vindicates Targeted Approach
Ken Garber
SCIENCE (2009)
STATs in cancer inflammation and immunity: a leading role for STAT3
Hua Yu et al.
NATURE REVIEWS CANCER (2009)
Identification of a functional EGF-R/p60c-src/STAT3 pathway in colorectal carcinoma: Analysis of its long-term prognostic value
A. Tadlaoui Hbibi et al.
CANCER BIOMARKERS (2008)
mTORC1 promotes survival through translational control of Mcl-1
John R. Mills et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
A novel activating role of SRC and STAT3 on HGF transcription in human breast cancer cells
Michelle R. Sam et al.
MOLECULAR CANCER (2007)
7-bromoindirubin-3′-oxime induces caspase-independent cell death
J. Ribas et al.
ONCOGENE (2006)
3′-substituted 7-halogenoindirubins, a new class of cell death inducing agents
Yoan Ferandin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
A novel activating function of c-Src and Stat3 on HGF transcription in mammary carcinoma cells
EJ Wojcik et al.
ONCOGENE (2006)
Targeting STAT3 affects melanoma on multiple fronts
M Kortylewski et al.
CANCER AND METASTASIS REVIEWS (2005)
Newest findings on the oldest oncogene;: how activated src does it
MC Frame
JOURNAL OF CELL SCIENCE (2004)
Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases
P Polychronopoulos et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
The stats of cancer - New molecular targets come of age
H Yu et al.
NATURE REVIEWS CANCER (2004)
Roles of activated Src and Stat3 signaling in melanoma tumor cell growth
G Niu et al.
ONCOGENE (2002)
Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China
ZJ Xiao et al.
LEUKEMIA & LYMPHOMA (2002)
Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts:: Role of activated STAT3 signaling
D Sinibaldi et al.
ONCOGENE (2000)
Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity
Y Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein
S Pugazhenthi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
